Pharma
Novo Nordisk announces rebrand amid competition with Eli Lilly
The two pharma giants are in competition for dominance in the obesity and diabetes markets.
GLP-1s
How GLP-1s is shaping the future of healthcare, featuring expert insights, data-driven stories, and the latest industry developments.
Pharma
Pharma companies home in on GLP-2s and GLP-3s in race to innovate on obesity treatments
Companies are looking at combining several hormone-like molecules to boost results.
Pharma
Some telehealth GLP-1 prescriptions have little clinician oversight, little regulation
A recent study from JAMA highlights what some worry are gaps in regulation.
Pharma
3 treatments from 2026 that could alter the future of medicine
We’re diving into new medicines and why they matter.
Pharma
Samsung, Massachusetts General Hospital team up to study GLP-1 muscle loss
Galaxy Watch wearers will get alerts about health and exercise to see if they can maintain their strength.
Pharma
How Eli Lilly’s oral GLP-1 could change the obesity drug market
A hot new GLP-1 bombshell has entered the villa.
Pharma
Pfizer, Novo Nordisk bidding war is just the latest escalation of a lucrative GLP-1 race
The G in GLP-1 might as well stand for gold.
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.
By subscribing, you accept our Terms & Privacy Policy.
